Comparative expression profile of CD10 and cyclin D1 in cutaneous histiocytofibroma and dermatofibrosarcoma

Dermatofibrosarcoma protuberans (DFSP) and histiocytofibroma (HF) are two rare fibrohistiocytic tumors, with some overlapping pathologic features. Immunohistochemistry is very useful in these cases. CD34 is a commonly used marker. However, the increasing cases of CD34 negative DFSP make it pressing...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunoassay & immunochemistry 2021-07, Vol.42 (4), p.347-358
Main Authors: Kouki, Nadia, Ben Rejeb, Sarra, Cherif, Ines, Ghozzi, Amen, Chelly, Ines, Bellil, Khadija, Haouet, Slim
Format: Article
Language:English
Subjects:
AKT protein
Biomarkers
CD34 antigen
Collagen (type I)
Cyclin D1
Dermatofibrosarcoma
Dermatofibrosarcoma protuberans
Diagnosis
Differential diagnosis
fibrohistiocytic tumors
histiocyotofibroma
Immunohistochemistry
Mesenchyme
Platelet-derived growth factor
Skin
TOR protein
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dermatofibrosarcoma protuberans (DFSP) and histiocytofibroma (HF) are two rare fibrohistiocytic tumors, with some overlapping pathologic features. Immunohistochemistry is very useful in these cases. CD34 is a commonly used marker. However, the increasing cases of CD34 negative DFSP make it pressing to test other immunohistochemical markers that could help in the differential diagnosis. DFSP is known to harbor COL1A1-PDGFB rearrangement. Tumors in the differential diagnosis of DFSP usually lack this molecular signature. Recent studies suggested the interaction of PDGFB and PDGF receptor b with various signaling pathways, including the Akt-mTOR pathway. Cyclin D1, one of the oncoproteins activated in this pathway, may represent a promising useful biomarker in the differential diagnosis. On the other hand, CD10 expression in specialized mesenchymal skin cells, and especially in fibrohistiocytic skin tumors has been reported, which raises the interest of using this biomarker in HF and DFSP. In this study, we aimed to compare the expression of CD10 and cyclin D1 in 15 cases of DFSP and 15 cases of HF and discuss their potential contribution in the differential diagnosis.
ISSN:1532-1819
1532-4230
DOI:10.1080/15321819.2020.1868000